TG Therapeutics, Inc. (NASDAQ:TGTX) Shares Acquired by E Fund Management Co. Ltd.

E Fund Management Co. Ltd. lifted its holdings in TG Therapeutics, Inc. (NASDAQ:TGTX) by 7.8% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 23,554 shares of the biopharmaceutical company’s stock after acquiring an additional 1,711 shares during the quarter. E Fund Management Co. Ltd.’s holdings in TG Therapeutics were worth $709,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the business. State Street Corp increased its stake in shares of TG Therapeutics by 35.8% in the third quarter. State Street Corp now owns 9,094,158 shares of the biopharmaceutical company’s stock worth $212,712,000 after acquiring an additional 2,398,015 shares during the period. Charles Schwab Investment Management Inc. boosted its holdings in TG Therapeutics by 7.2% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,269,513 shares of the biopharmaceutical company’s stock worth $38,212,000 after buying an additional 84,904 shares in the last quarter. Bank of New York Mellon Corp boosted its holdings in TG Therapeutics by 10.5% during the fourth quarter. Bank of New York Mellon Corp now owns 923,488 shares of the biopharmaceutical company’s stock worth $27,797,000 after buying an additional 87,679 shares in the last quarter. Principal Financial Group Inc. boosted its holdings in TG Therapeutics by 7.5% during the fourth quarter. Principal Financial Group Inc. now owns 830,184 shares of the biopharmaceutical company’s stock worth $24,989,000 after buying an additional 57,996 shares in the last quarter. Finally, JPMorgan Chase & Co. boosted its holdings in TG Therapeutics by 60.0% during the third quarter. JPMorgan Chase & Co. now owns 720,798 shares of the biopharmaceutical company’s stock worth $16,859,000 after buying an additional 270,286 shares in the last quarter. Institutional investors and hedge funds own 58.58% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on TGTX shares. JPMorgan Chase & Co. increased their price target on shares of TG Therapeutics from $30.00 to $43.00 and gave the stock an “overweight” rating in a report on Monday, November 25th. HC Wainwright reissued a “buy” rating and set a $55.00 price target on shares of TG Therapeutics in a report on Tuesday. Finally, StockNews.com raised shares of TG Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $40.67.

TG Therapeutics Stock Performance

TGTX opened at $38.44 on Friday. The company has a quick ratio of 3.91, a current ratio of 4.59 and a debt-to-equity ratio of 1.27. The company has a market cap of $5.98 billion, a price-to-earnings ratio of -384.36 and a beta of 2.30. TG Therapeutics, Inc. has a 52-week low of $12.93 and a 52-week high of $38.58. The firm’s fifty day simple moving average is $30.95 and its two-hundred day simple moving average is $28.43.

TG Therapeutics (NASDAQ:TGTX) last posted its quarterly earnings data on Monday, March 3rd. The biopharmaceutical company reported $0.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.08 by $0.07. The business had revenue of $108.19 million for the quarter, compared to the consensus estimate of $100.67 million. TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. Equities analysts anticipate that TG Therapeutics, Inc. will post 0.08 earnings per share for the current fiscal year.

Insider Buying and Selling at TG Therapeutics

In other TG Therapeutics news, CFO Sean A. Power sold 10,021 shares of the stock in a transaction on Monday, January 6th. The shares were sold at an average price of $28.53, for a total transaction of $285,899.13. Following the transaction, the chief financial officer now directly owns 660,611 shares of the company’s stock, valued at $18,847,231.83. This trade represents a 1.49 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 10.50% of the company’s stock.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.